文献速递心力衰竭与心肌病

区域与种族/族裔对恩格列净在射血分数降低心衰患者中疗效的影响:EMPEROR-Reduced 试验

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
PubMed 文献 · Eur Heart J · 2021-01-01

基于 EMPEROR-Reduced 试验 3730 例患者的分析,探索区域和种族/族裔对恩格列净疗效的影响。安慰剂组主要心衰事件发生率因区域和种族而异,心衰住院与心血管死亡比值最高的亚组恩格列净获益最显著;扩展心衰事件定义纳入门诊心衰恶化后,区域差异减弱。

要点

  • 安慰剂组主要终点事件率因区域和种族/族裔不同:亚洲 27.7、北美 26.4、拉美 21.4、欧洲 17.5/100 患者年。
  • 心衰住院与心血管死亡比值最高的亚组(亚洲 5.4、北美 4.8)恩格列净对主要终点的降低最显著。
  • 扩展心衰事件定义纳入门诊心衰恶化后,欧洲安慰剂事件率增加,恩格列净相对风险降低从 6% 增至 26%。

核心结论

  • 不同区域和种族/族裔间主要心衰事件的安慰剂事件率存在显著差异。
  • 恩格列净的获益在心衰住院与心血管死亡比值最高的亚组中最明显。
  • 当心衰事件定义扩展至包含门诊心衰恶化时,区域差异减弱。

研究设计与样本

  • EMPEROR-Reduced 试验的事后分析,共纳入 3730 例慢性射血分数降低心衰患者。
  • 患者分布:欧洲 1353 例(36.3%),拉丁美洲 1286 例(34.5%),北美 425 例(11.4%),亚洲 493 例(13.2%)。
  • 种族/族裔分布:白人 2629 例(70.5%),黑人 257 例(6.9%),亚洲人 672 例(18.0%)。

主要发现

  • 安慰剂组心血管死亡或心衰住院事件率(每 100 患者年):亚洲 27.7,北美 26.4,拉丁美洲 21.4,欧洲 17.5。
  • 按种族/族裔:黑人 34.4,亚洲人 24.3,白人 18.7;差异主要由心衰住院驱动。
  • 心衰住院与心血管死亡比值:亚洲 5.4、北美 4.8、欧洲 2.1;黑人 4.8、亚洲人 4.2、白人 2.2。
  • 纳入门诊心衰恶化事件后,欧洲事件数增加,欧洲安慰剂事件率较其他区域增强,恩格列净在欧洲的相对风险降低从 6% 增至 26%。

临床怎么用

  • 临床中应关注不同区域和种族/族裔患者心衰事件率的基线差异,尤其是心衰住院风险。
  • 对于心衰住院与心血管死亡比值较高的患者群体,恩格列净的获益可能更显著。
  • 评估恩格列净疗效时,考虑将门诊心衰恶化事件纳入终点定义可能更全面反映区域差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this article is to explore the influence of region and race/ethnicity on the effects of empagliflozin in the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) trial. METHODS AND RESULTS: Of 3730 patients, 1353 (36.3%) were enrolled in Europe, 1286 (34.5%) in Latin America, 425 (11.4%) in North America, and 493 (13.2%) in Asia; 2629 (70.5%) were White, 257 (6.9%) Black, and 672 (18.0%) Asian. Placebo event rates (per 100 patient-years) for cardiovascular death or heart failure (HF) hospitalization varied by region (Asia 27.7, North America 26.4, Latin America 21.4, and Europe 17.5) and race/ethnicity (Black 34.4, Asian 24.3, and White 18.7); driven by differences in HF hospitalization. The ratio of total HF hospitalization to cardiovascular death varied from 5.4 in Asia and 4.8 in North America to 2.1 in Europe; and from 4.8 in Black and 4.2 in Asian to 2.2 in White patients. Groups with the highest ratio had the greatest reduction in the primary outcome with empagliflozin. Inclusion of outpatient worsening HF episodes added more events in Europe vs. other regions; enhanced the placebo event rates in Europe vs. other regions; and increased the relative risk reduction with empagliflozin in Europe from 6% to 26%. CONCLUSIONS: There were notable differences in the placebo event rates for major HF events across diverse regions and race/ethnic groups. The benefit of empagliflozin was most pronounced in groups with the highest ratio of HF hospitalization to cardiovascular death. Regional differences were attenuated when the definition of HF events was expanded to include outpatient worsening HF events.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lam CSP, Ferreira JP, Pfarr E, et al. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021. PMID: 34184057. doi:10.1093/eurheartj/ehab360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。